Compare KWR & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KWR | VCEL |
|---|---|---|
| Founded | 1918 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 1985 | 1997 |
| Metric | KWR | VCEL |
|---|---|---|
| Price | $134.61 | $36.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $149.25 | $60.40 |
| AVG Volume (30 Days) | 135.6K | ★ 626.9K |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.49% | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $1,864,242,000.00 | $258,716,999.00 |
| Revenue This Year | $3.44 | $17.86 |
| Revenue Next Year | $4.15 | $18.55 |
| P/E Ratio | ★ N/A | $149.06 |
| Revenue Growth | 0.08 | ★ 14.05 |
| 52 Week Low | $95.91 | $29.24 |
| 52 Week High | $161.47 | $63.00 |
| Indicator | KWR | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 51.30 | 44.89 |
| Support Level | $133.49 | $37.28 |
| Resistance Level | $138.90 | $42.68 |
| Average True Range (ATR) | 4.86 | 1.80 |
| MACD | 0.24 | -0.50 |
| Stochastic Oscillator | 54.42 | 4.42 |
Quaker Houghton manufactures and sells a variety of industrial process fluids. The product portfolio of the company includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids and surface treatment chemicals. The geographic segments of the company include America, EMEA, Asia/Pacific, and Global Specialty Businesses. The majority of the revenue is earned from America.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.